Bioequivalence and Bioavailability Forum 10:28 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-06-26 14:40

Posting: # 18968
Views: 1,413
 

 EMA: 2 product-specific guidances adopted [BE/BA News]

Dear all,

on 31 May the EMA’s CHMP adopted new product-specific guidance (effective with 1 December 2018):
  1. Dabigatran etexilate hard capsule 75 mg, 110 mg and 150 mg
  2. Dimethyl fumarate gastro-resistant capsule 120 mg and 240 mg
On the first one only Boehringer commented. IMHO, dabigatran is a NTID but I didn’t have the time to comment.
I suggested to delete “Comparable median and range for tlag” from the second one:


Comment:

For gastric-resistant formulations any [sic] difference in tlag is reflected in tmax as well. In other words: Any shift in tlag will lead to exactly the same shift in tmax.
Whereas rich sampling close to the expected tmax likely is already applied in the study (in order to get reliable estimates of Cmax) this is generally not the case around the expected tlag. In order to get reliable estimates of tlag, additional samples would have to be drawn in the absorption phase.

Concerns:

  1. Unnecessary burden to the subjects renders this requirement ethically doubtful.
  2. Contrary to Cmax, early concentrations might be close to the analytical limit of quantification – which leads to high variability and hence, likely ill-defined estimates of tlag.
  3. (As in other guidelines) it is an unresolved question what a “comparable” median is.
  4. The range has a breakdown point of one (i.e., a single extreme value distorts the estimate towards this value).
    Example: Values after both the test and reference product are identical and 1. If we add another subject with T=1 and R=24, the medians will be still 1 for both products. For T the range will be 0 but for R it will be 23. This lacks any relevance.

Proposed change:

Remove tlag from the required PK variables.



Was obviously accepted (even tmax removed…) but comments not published.
Am I a persona non grata?

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
mmw
Junior

India,
2018-06-29 07:20

@ Helmut
Posting: # 18993
Views: 980
 

 EMA: New product-specific draft guidances published

Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-07-05 15:11

@ mmw
Posting: # 19023
Views: 844
 

 EMA: New product-specific draft guidance published


Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-08-03 16:52

@ Helmut
Posting: # 19133
Views: 585
 

 EMA: 5 product-specific guidances adopted

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,260 registered users;
online 19 (0 registered, 19 guests [including 11 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed